12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Other News

Merck KGaA neurology news

The Merck Serono S.A. division of Merck launched Asceneuron S.A. (Geneva, Switzerland) to develop the division's preclinical Alzheimer's disease (AD) programs targeting microtubule-associated protein-tau (MAPT; TAU, FTDP-17) and beta amyloid. Asceneuron will develop...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >